Publication: Successful treatment of arrhythmia with β-blocker and flecainide combination in pregnant patients with Andersen–Tawil syndrome: A case report and literature review
Issued Date
2020-01-01
Resource Type
ISSN
1542474X
1082720X
1082720X
Other identifier(s)
2-s2.0-85091197270
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Annals of Noninvasive Electrocardiology. (2020)
Suggested Citation
Pongprueth Rujirachun, Apichaya Junyavoraluk, Manop Pithukpakorn, Bhoom Suktitipat, Arjbordin Winijkul Successful treatment of arrhythmia with β-blocker and flecainide combination in pregnant patients with Andersen–Tawil syndrome: A case report and literature review. Annals of Noninvasive Electrocardiology. (2020). doi:10.1111/anec.12798 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/59248
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Successful treatment of arrhythmia with β-blocker and flecainide combination in pregnant patients with Andersen–Tawil syndrome: A case report and literature review
Other Contributor(s)
Abstract
© 2020 The Authors. Annals of Noninvasive Electrocardiology published by Wiley Periodicals LLC. Andersen–Tawil syndrome (ATS) is a rare disorder characterized by a triad of ventricular arrhythmia (VA), dysmorphic features, and periodic paralysis. Due to the rarity of this condition, less is known about physiologic effect of pregnancy to ATS and arrhythmia. There is no established guideline for peripartum or postpartum treatment and prevention of arrhythmia in ATS; thus, the clinical management is challenging. We reported two KCNJ2-associated ATS patients who got pregnant and underwent vaginal birth safely. Both individuals had VA, micrognathia without periodic paralysis. β-blocker plus flecainide could be an effective treatment combination when monotherapy failed to control arrhythmia. VA of two pregnant patients with ATS could be controlled by either physiologic changes associated pregnancy or the combination treatment of β-blocker and flecainide.